CONDOR (CRTH258D2301) A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation lase in patients with proliferative diabetic retinopathy.

TALON-EXTENSION (CRTH258A2303E1) A 56-week, phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6 mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study

XPAND (BAYBAY21/21912) A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive Customized Treatment Intervals in Patients ≥50 Years of Age with No Fluid Due to Choroidal Neovascularization (CNV) Lesions Secondary to Neovascular (wet) Age-related Macular Degeneration (nAMD) Following Treatment Initiation with Aflibercept

ACUITY (ACT-01_P2_01) A randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ACT-01 in patients with acute optic neuritis